What if I'm on a shared care agreement and can't get my ADHD medication?

Under a shared care agreement, your specialist retains clinical responsibility for treatment decisions while your GP handles repeat prescriptions. If your medication is unavailable, your GP should contact your specialist for advice on switching. In practice, this can be slow. To speed things up: contact your ADHD service directly to request urgent switching advice, ask your GP to send an urgent clinical query via NHS e-Referral or email, and keep a record of when you last had medication so the specialist understands the urgency. Do not simply stop taking ADHD medication without medical advice.

Is Elvanse still in shortage in the UK in 2026?

Elvanse (lisdexamfetamine) supply has improved significantly since the worst of the shortage in 2023-2024. Most strengths are now available, and ADHD services can resume initiating new patients on Elvanse. However, intermittent supply issues persist for 40mg and 60mg strengths. The manufacturer Takeda has increased production capacity. The DHSC recommends using the 30mg, 50mg, and 70mg titration schedule where possible to avoid the constrained strengths.

Is Concerta XL (methylphenidate) available in the UK?

Methylphenidate prolonged-release tablets, including Concerta XL, remain in limited supply with intermittent regional disruptions as of March 2026. Generic equivalents like Xaggitin XL and Matoride XL are also affected. Equasym XL modified-release capsules remain available but cannot support large increases in demand. Your prescriber may recommend switching to lisdexamfetamine (Elvanse) if methylphenidate is consistently unavailable.

Why has the ADHD medication shortage lasted so long?

The ADHD shortage has persisted since late 2023 because the underlying cause — a rapid increase in demand — has not been resolved. UK ADHD prescriptions have risen over 20% year-on-year since 2020. Manufacturing of Schedule 2 controlled substances requires Home Office raw material quotas, MHRA-inspected facilities, and cannot simply be scaled up overnight. Even as manufacturers increase capacity, demand continues to grow. The NHS Right to Choose pathway and private ADHD assessment services have significantly increased diagnosis rates. The shortage will likely only fully resolve when manufacturing capacity catches up with the new baseline demand level.

What non-medication support is available during ADHD medication shortages?

While medication is a key part of ADHD management, non-pharmacological support can help bridge gaps: cognitive behavioural therapy (CBT) adapted for ADHD, occupational therapy for practical coping strategies, ADHD coaching, structured routines and environmental modifications, exercise (evidence shows cardiovascular exercise can temporarily improve ADHD symptoms), and peer support through organisations like ADHD UK and the ADHD Foundation. These are not replacements for medication for most people, but they can help manage symptoms during a shortage period. Ask your GP for referrals to local ADHD support services.

ADHD Medication Shortage UK 2026

The UK's ADHD medication crisis is now in its third year. What started as scattered supply issues in late 2023 has become the longest-running medication shortage in recent NHS history. This page is your central hub — not a repeat of individual medicine pages, but an overview of the entire ADHD medication landscape in the UK: why demand has outstripped supply, how every ADHD medication compares, what the shortage timeline looks like, and a practical flowchart for what to do when you can't get your prescription filled. MediWatch tracks live status from official DHSC data.

The UK ADHD Medication Landscape

ADHD (Attention Deficit Hyperactivity Disorder) is one of the most commonly diagnosed neurodevelopmental conditions in the UK. The numbers tell a stark story:

An estimated 1.9 million adults in the UK have ADHD, though the majority remain undiagnosed (ADHD UK, 2025)
ADHD prescriptions in England rose by over 20% year-on-year from 2020 to 2024, according to NHSBSA prescribing data
The number of ADHD medication items dispensed in England reached over 6 million per year by 2025, up from approximately 3.5 million in 2019
Growth is driven by increased adult diagnosis rates, the NHS Right to Choose pathway enabling access to private ADHD assessments, and greater public awareness following media coverage and social media
Meanwhile, manufacturing capacity has not kept pace — ADHD medications are Schedule 2 controlled drugs requiring Home Office raw material quotas, MHRA-inspected facilities, and regulatory approvals that prevent rapid scaling

The result: a widening gap between demand and supply that has persisted since late 2023 with no clear end date. Multiple manufacturers — including Takeda (Elvanse), Janssen (Concerta XL), and several generics producers — have increased production, but demand continues to grow faster than capacity comes online.

This page vs individual medicine pages: Each ADHD medication has its own detailed page on MediWatch (linked below) with specific shortage details, formulation information, and individual FAQs. This hub page provides the overview and comparison — use it to understand the full picture, then drill into specific medicines for detailed status.

Quick Status: All ADHD Medications

Elvanse (lisdexamfetamine) Methylphenidate MR Concerta XL Guanfacine (Intuniv) Lisdexamfetamine Atomoxetine (Strattera) Dexamfetamine

ADHD Medication Comparison Table

This table compares all ADHD medications available in the UK — their type, formulations, typical doses, and current supply status. This side-by-side view is unique to this hub page and is designed to help you and your prescriber evaluate alternatives quickly:

Medication	Type	Formulations	Typical Adult Dose	Duration of Action	Supply Status (Mar 2026)
Methylphenidate IR Ritalin, Medikinet	Stimulant	Tablets 5mg, 10mg, 20mg	10–60mg/day in divided doses	3–4 hours	Generally available
Methylphenidate MR Concerta XL, Xaggitin XL, Matoride XL, Delmosart	Stimulant	Tablets 18mg, 27mg, 36mg, 54mg	18–54mg once daily	10–12 hours	Limited — intermittent disruptions
Methylphenidate MR capsules Equasym XL, Medikinet XL	Stimulant	Capsules 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg	10–60mg once daily	8 hours (Equasym), 8 hours (Medikinet)	Available but limited capacity
Lisdexamfetamine Elvanse, Elvanse Adult	Stimulant (prodrug)	Capsules 20mg, 30mg, 40mg, 50mg, 60mg, 70mg	30–70mg once daily	13–14 hours	Improving — 40mg/60mg constrained
Dexamfetamine Amfexa, generic	Stimulant	Tablets 5mg (generic), 5mg/10mg/20mg (Amfexa)	5–20mg 2–3x daily	4–6 hours	Available — cannot support large demand increase
Atomoxetine Strattera, generics	Non-stimulant (NRI)	Capsules 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg	40–100mg once daily	24 hours (continuous)	Available
Guanfacine Intuniv	Non-stimulant (α2-agonist)	MR tablets 1mg, 2mg, 3mg, 4mg	1–4mg once daily (children/adolescents)	24 hours (continuous)	2mg & 3mg out of stock

Key for prescribers: Stimulants (methylphenidate and amfetamines) are first-line for ADHD per NICE NG87. Atomoxetine and guanfacine are second-line options when stimulants are ineffective, not tolerated, or contraindicated (e.g. tic disorders, substance misuse history, cardiovascular concerns). All stimulant ADHD medications are Schedule 2 controlled drugs.

Current Active Shortages — Detail

Methylphenidate Prolonged-Release Tablets

Methylphenidate prolonged-release tablets

Limited Supply DHSC MSN

Methylphenidate prolonged-release tablet brands are in limited supply with intermittent regional disruptions. This includes Concerta XL, Xaggitin XL, Matoride XL, and Delmosart MR.

Available alternatives: Lisdexamfetamine (Elvanse) capsules can support increased demand. Equasym XL capsules available but limited. Unlicensed methylphenidate prolonged-release tablets can be sourced with varying lead times.

Methylphenidate is the first-line treatment for ADHD in both children and adults in the UK, as recommended by NICE. The prolonged-release formulations allow once-daily dosing, which is particularly important for school-age children and working adults who need consistent symptom control throughout the day. The intermittent regional disruptions mean stock may be available at one pharmacy but not another — it's worth phoning around before assuming it's completely unavailable.

Lisdexamfetamine (Elvanse)

Lisdexamfetamine (Elvanse) capsules

Improving DHSC MSN

Supply has improved across most strengths. Intermittent issues remain with Elvanse 40mg, Elvanse Adult 40mg and Elvanse 60mg capsules.

Available alternatives: Elvanse 30mg, 50mg, and 70mg can support increased demand. Generic dexamfetamine 5mg tablets and Amfexa 5mg/10mg/20mg tablets remain available. ADHD services can now resume initiating new patients on Elvanse.

Elvanse is a prodrug — it is converted to dexamfetamine in the body, giving a smoother onset and lower abuse potential than immediate-release stimulants. It has the longest duration of action of any ADHD stimulant (13–14 hours), making it popular for adults. The manufacturer, Takeda, has been actively working to increase production capacity. The DHSC has recommended using the 30mg/50mg/70mg titration schedule where possible to avoid the constrained 40mg and 60mg strengths.

Guanfacine (Intuniv)

Guanfacine (Intuniv) 2mg & 3mg modified-release tablets

Medium DHSC MSN

Guanfacine 2mg and 3mg MR tablets have been out of stock. Guanfacine 1mg and 4mg MR tablets remain available but cannot support increased demand.

Guanfacine is a non-stimulant ADHD medication licensed in the UK for children and adolescents aged 6–17 years. It acts on alpha-2 adrenergic receptors in the prefrontal cortex. It's used when stimulants are unsuitable (e.g. tic disorders, anxiety, substance misuse risk) or as an add-on when stimulants alone don't provide adequate symptom control. It is not a controlled drug, which means prescriptions can be issued electronically and in larger quantities — but supply constraints remain.

Shortage Timeline: 2023–2026

Understanding when and how the ADHD shortage developed helps you understand why it's been so difficult to resolve:

October 2023

First DHSC notifications

The DHSC issues Medicine Supply Notifications for methylphenidate prolonged-release tablets and lisdexamfetamine capsules. Initial notifications describe "intermittent supply issues" but the scale is not yet apparent. Pharmacies begin reporting difficulty sourcing stock.

December 2023 – February 2024

Crisis escalates

Shortages spread across all methylphenidate MR brands and most Elvanse strengths. ADHD UK reports thousands of patients contacting them for help. Media coverage intensifies. The DHSC advises clinicians to delay initiating new patients on Elvanse and to consider alternative stimulants. Pharmacies report patients travelling over 50 miles to find stock.

March – June 2024

Manufacturer commitments

Takeda (Elvanse) announces production capacity expansion. Generic methylphenidate manufacturers pledge increased output. The Home Office agrees to raise raw material quotas for controlled substance precursors. However, new capacity takes 6–12 months to come online.

July – December 2024

Partial improvement

Elvanse supply gradually improves for 30mg, 50mg, and 70mg strengths. Methylphenidate MR remains problematic. Guanfacine 2mg and 3mg stock becomes unreliable. ADHD services resume cautious initiation of new Elvanse patients. Regional variation becomes pronounced — London and South East generally better stocked than Northern England, Wales, and Scotland.

January – March 2025

New equilibrium

Supply improves across the board but doesn't fully normalise. ADHD prescriptions continue rising (new diagnoses still outpacing resolved ones). Manufacturers operate at increased capacity but demand keeps growing. The DHSC downgrades methylphenidate shortage status to "potentially resolved" though pharmacies still report intermittent issues.

2025–2026

Ongoing steady state

The shortage enters a chronic phase — not acute crisis, but persistent undersupply. Certain strengths and brands remain intermittently unavailable. Patients have adapted (many switched medications during the crisis) but the system remains fragile. Any demand spike (e.g. new-year new-patient intake, university terms starting) can cause localised stock-outs.

Why Demand Has Outstripped Supply

The ADHD medication shortage is fundamentally a demand-side problem that the supply side cannot resolve quickly due to regulatory constraints on controlled drug manufacturing:

The Diagnosis Boom

NHS Right to Choose: This pathway allows NHS patients to choose to be assessed by any qualified provider, including private ADHD assessment services like Psychiatry-UK. It dramatically shortened assessment wait times from 3–5 years in some areas to a few months, releasing a backlog of undiagnosed patients into the treatment pipeline.
Private diagnosis growth: Dozens of private ADHD assessment services have launched since 2020, making diagnosis accessible to many who wouldn't have been assessed through traditional NHS pathways.
Social media awareness: TikTok and other platforms dramatically increased public awareness of ADHD symptoms, particularly in adults who had never been assessed. While raising awareness is positive, it created an unprecedented spike in assessment requests.
COVID-19 effect: Remote working and changed routines made many adults newly aware of attention difficulties they had previously managed through structure and routine.

The Manufacturing Bottleneck

Schedule 2 controlled substances — Methylphenidate and amfetamine-based medications require Home Office quotas for raw material procurement, licensed manufacturing facilities with enhanced security, and additional regulatory oversight at every stage.
Scaling takes time — A pharmaceutical manufacturer cannot simply produce more tablets next month. New production capacity requires facility modifications, regulatory inspections, stability testing, and batch validation — a process that typically takes 12–18 months minimum.
Limited suppliers — The UK market for ADHD medications is concentrated among a small number of manufacturers. Elvanse is made exclusively by Takeda. Concerta XL by Janssen. There is no backup capacity if a single production line goes down.

Prescribing Data

NHSBSA data shows the scale of growth. Items dispensed for ADHD medications in England:

Year	Approx. Items Dispensed (England)	Year-on-Year Change
2019	~3.5 million	—
2020	~3.8 million	+9%
2021	~4.3 million	+13%
2022	~5.0 million	+16%
2023	~5.7 million	+14%
2024	~6.2 million	+9%

Source: NHSBSA prescription data (England only). Figures rounded. Includes all ADHD medications. Northern Ireland, Scotland, and Wales data published separately.

Can't Get Your ADHD Medication? Here's Exactly What To Do

This step-by-step flowchart guides you through every option, with branching paths depending on your situation:

Contact your pharmacy — ask specific questions

"Is this a local stock issue or a national shortage?" and "When is your next delivery from the wholesaler?" and "Can you check other branches in your chain?" A local stock-out may resolve in 24–48 hours.

If local stock-out → Ask them to hold your prescription and order for the next delivery. It should arrive within 1–2 days.

If national shortage → Continue to step 2.

Phone 3–5 other pharmacies

ADHD medication stock varies significantly between pharmacies and regions. Try independents, supermarket pharmacies (Asda, Tesco, Sainsbury's), and pharmacies in neighbouring towns. Ask specifically for your exact medication, strength, and brand.

If you find stock → Ask your current pharmacy to transfer your prescription, or collect a new one from your prescriber. Note: controlled drug prescriptions cannot be transferred between pharmacies in most cases — you may need a new prescription directed to the pharmacy with stock.

If no stock anywhere → Continue to step 3.

Contact your ADHD prescriber (not just your GP)

Switching ADHD medications requires specialist input. Contact your psychiatrist, ADHD specialist nurse, or ADHD clinic directly. If you're under shared care, your specialist retains clinical responsibility for treatment decisions. Ask about: switching to an available strength, switching formulation (e.g. tablets to capsules), or switching drug class.

If on shared care → Your GP can prescribe the alternative recommended by your specialist without a full review. Ask the specialist to send switching advice to your GP urgently.

If you can't reach your specialist → Ask your GP to send an urgent clinical query to the specialist team. In the meantime, continue to step 4.

Request an emergency supply

Any pharmacist can provide an emergency supply of up to 5 days of a Schedule 2 controlled drug (ADHD stimulants) at their professional discretion. You don't need a prescription. State that you have an immediate clinical need and that it is impractical to obtain a new prescription in time. There may be a charge for this service.

Note: Emergency supplies of controlled drugs are limited to 5 days (not 30 days as for non-controlled medications). This buys you time to arrange a switch or find alternative stock.

Plan for ongoing supply

Sign up for MediWatch alerts for your specific medications. Order repeat prescriptions 7–10 days early. Ask your prescriber about a backup medication plan. Build a relationship with your pharmacist so they can flag supply issues proactively. Consider whether a different formulation or brand that's better supplied could work for you long-term.

⚠️ Important — Do Not Self-Manage ADHD Medication Changes

ADHD medications are controlled drugs (Schedule 2). Never adjust doses, split capsules, combine different medications, or switch brands without clinical guidance. The dose equivalences between different ADHD drugs are not straightforward — 20mg of methylphenidate is not the same as 20mg of lisdexamfetamine. Your prescriber needs to manage any switch.

Regional Variation

ADHD medication availability is not uniform across the UK. Based on patient reports, pharmacy surveys, and MediWatch data:

London & South East: Generally better stocked due to higher pharmacy density and proximity to wholesale distribution centres. More options for patients to pharmacy-hop.
Northern England: More persistent supply gaps reported, particularly in smaller towns. Fewer independent pharmacies means less wholesale diversity.
Scotland: Additional supply challenges due to separate wholesaler arrangements and the Scottish Drug Tariff. Pharmacy density in rural areas (Highlands, Islands) makes shortages more impactful — fewer alternatives within practical travel distance.
Wales: Similar pattern to Northern England. Welsh NHS structures mean slightly different response mechanisms.
Northern Ireland: Cross-border effects — some patients report accessing medications in the Republic of Ireland, though this requires a separate prescription from an Irish-registered prescriber.
University towns: Areas with large student populations (e.g. Manchester, Leeds, Bristol, Edinburgh) can see localised demand spikes at the start of term as students present prescriptions.

Support Organisations & Helplines

ADHD UK

The UK's leading ADHD charity. Provides support, medication shortage updates, and advocacy. Their shortage tracker is a valuable patient-reported resource alongside official DHSC data.

🌐 adhduk.co.uk · 📧 [email protected]

ADHD Foundation

Neurodiversity charity providing training, resources, and support for individuals, families, and professionals. Offers an ADHD helpline for medication and diagnostic queries.

🌐 adhdfoundation.org.uk · 📞 0151 541 9020

AADD-UK (Adults with ADHD)

Specifically supports adults diagnosed with or seeking assessment for ADHD. Provides peer support groups, information resources, and a forum for sharing medication availability experiences.

🌐 aadduk.org

NICE ADHD Guidelines (NG87)

The official clinical guideline for ADHD diagnosis and management. Useful to reference when discussing treatment options with your prescriber — it sets out the evidence for each medication and the recommended treatment pathway.

🌐 nice.org.uk/guidance/ng87

NHS 111

If you are in immediate need of medication and cannot access your prescriber, NHS 111 can help arrange emergency supplies or connect you with out-of-hours services.

📞 111 (free from any phone, 24/7)

Frequently Asked Questions

These FAQs cover hub-level questions about the ADHD shortage landscape. For medication-specific questions, see the individual medicine pages linked above.

Can my GP prescribe an alternative ADHD medication?

GPs can prescribe some ADHD medications, but switching between ADHD drugs ideally requires specialist input. If you're on a shared care agreement, your GP manages repeat prescriptions under guidance from a psychiatrist. They can prescribe a different formulation of the same drug (e.g. switching from Concerta XL to Equasym XL, both methylphenidate) relatively easily. Switching drug class entirely — for example from methylphenidate to lisdexamfetamine — should involve your ADHD specialist. Contact your prescribing psychiatrist or ADHD service first. If wait times are long, ask your GP to make an urgent clinical query to the specialist team.

What if I'm on a shared care agreement and can't get supply?

Under a shared care agreement, your specialist retains clinical responsibility for treatment decisions while your GP handles repeat prescriptions. If your medication is unavailable, your GP should contact your specialist for switching advice. To speed things up: contact your ADHD service directly, ask your GP to send an urgent clinical query via NHS e-Referral or email, and keep a record of when you last had medication so the specialist understands the urgency. Do not simply stop taking ADHD medication without medical advice.

Are ADHD medication shortages worse in certain UK regions?

Yes, shortages vary significantly by region. Urban areas with more pharmacies tend to have better availability. Rural areas and parts of Scotland, Wales, and Northern Ireland report more persistent gaps. Areas with large ADHD clinics or universities can see higher local demand. There is no official DHSC data on regional variation, but patient reports consistently show a postcode lottery. If your local pharmacy is consistently out of stock, try pharmacies in nearby towns or larger cities.

Why has the ADHD shortage lasted so long?

The underlying cause — rapidly growing demand — has not been resolved. UK ADHD prescriptions have risen over 20% year-on-year since 2020. Manufacturing of Schedule 2 controlled substances requires Home Office quotas, MHRA-inspected facilities, and cannot be scaled quickly. Even as manufacturers increase capacity, demand continues to grow. The shortage will likely only fully resolve when manufacturing catches up with the new baseline demand level — and that demand may continue rising for several more years.

Can I get ADHD medication from a private prescription or online pharmacy?

Private prescriptions and online pharmacies source from the same UK wholesale supply chain, so they face the same shortages. A private prescription does not give you priority access. Some online pharmacies may occasionally have stock when local ones don't, but this isn't guaranteed. Be extremely cautious of any service offering ADHD medications that are "guaranteed available" — this may indicate unlicensed or counterfeit products. Always use pharmacies registered with the General Pharmaceutical Council (GPhC).

What non-medication support is available during shortages?

While medication is key to ADHD management for most people, non-pharmacological support can help bridge gaps: CBT adapted for ADHD, occupational therapy, ADHD coaching, structured routines, regular cardiovascular exercise (evidence shows it temporarily improves ADHD symptoms), and peer support through ADHD UK and the ADHD Foundation. Ask your GP for referrals to local ADHD support services. These are not replacements for medication, but can help manage symptoms during a shortage period.

Is the ADHD medication shortage likely to end in 2026?

A full resolution in 2026 is unlikely. While supply has improved significantly from the worst of the crisis in 2023–2024, demand continues to grow as more adults are diagnosed. Manufacturing capacity is increasing but lags behind. The most likely scenario is continued gradual improvement with intermittent regional disruptions. Full normalisation will require either demand stabilising (when the backlog of undiagnosed patients works through the system) or manufacturing capacity catching up — both of which may take until 2027–2028.

Related Condition Pages

Track your ADHD medications

Get free email alerts the moment Elvanse, Concerta or any of your medications face supply issues

Data sources: DHSC Medicine Supply Notifications · NHSBSA Prescribing Data · NICE NG87 · ADHD UK · ADHD Foundation · Specialist Pharmacy Service (SPS)
This page is updated when new shortage data is published. Last checked: 5 March 2026.